Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 198 participants.

Also called NCT07375966

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 198 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07375966
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07375966. Randomized; single masking; primary purpose treatment. Start 2026-03-25 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)
Acronym
RITIS-TNK2
Intervention (Drug)
Tenecteplase
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct07375966
Content hash
910a1d26e33840c17997e9e244d8ab014c3132bab229722410d503f9dbeb5a82